Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study

Overview of attention for article published in Frontiers in oncology, September 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,549 followers.

New research: Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study: Purpose Apatinib is an approved third-line treatment for metastatic gastric cancer in China and… https://t.

02 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.